Meeting
2022 ASCO Annual Meeting
Collaborative federated learning behind hospitals’ firewalls for predicting histological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
Authors
Jean Ogier du Terrail
Owkin, Paris, France
Jean Ogier du Terrail , Armand Leopold , Clément Joly , Mathieu Andreux , Charles Maussion , Benoit Schmauch , Mikhail Zaslavskiy , Gilles Wainrib , Maud Milder , Julie Gervasoni , Julien Guérin , Thierry Durand , Alain Livartowski , Kelvin Moutet , Clément Gautier , Anne-Laure Moisson , Camille Marini , Mathieu Galtier , Pierre Etienne Heudel , Guillaume Bataillon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 590)
DOI
10.1200/JCO.2022.40.16_suppl.590
Abstract #
590
Poster Bd #
361
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Artificial intelligence (AI)–powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).
First Author: Hee Jin Lee
Poster
2022 ASCO Annual Meeting
Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
First Author: David Groheux
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2018 ASCO Annual Meeting
Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.
First Author: Cornelia Liedtke